PIPA: A phase Ib study of β-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) and fulvestrant (FUL) in PIK3CA-mutant (mt) ER-positive and taselisib (T) plus palbociclib (P) in PIK3CA-mutant (mt) ER-negative advanced breast cancer.

Javier Pascual,Iain R. Macpherson,Anne C Armstrong,Sarah Emily Ward,Mona Parmar,Alison Joanne Turner,Hannah Bye,Paula Proszek,Andrew Dodson,Isaac Garcia-Murillas,Jenny King,Emma Hall,Laura Finneran,Juanita Lopez,A. Okines,Alistair Ring,Nicholas C. Turner

PIPA: A phase Ib study of β-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) and fulvestrant (FUL) in PIK3CA-mutant (mt) ER-positive and taselisib (T) plus palbociclib (P) in PIK3CA-mutant (mt) ER-negative advanced breast cancer.

2019

Javier Pascual
Iain R. Macpherson
Anne C Armstrong
Sarah Emily Ward
Mona Parmar
Alison Joanne Turner
Hannah Bye
Paula Proszek
Andrew Dodson
Isaac Garcia-Murillas
Jenny King
Emma Hall
Laura Finneran
Juanita Lopez
A. Okines
Alistair Ring
Nicholas C. Turner

1051Background: PI3K and CDK4/6 inhibitors synergise in ER+ve and –ve PIK3CA-mt breast cancer (BC) models. Escalation phase of this study set recommended phase 2 dose (RP2D) at P 125mg on a 3/1 sch...

Keywords:

Phosphatidylinositol
Palbociclib
PI3K/AKT/mTOR pathway
Breast cancer
Gene isoform
Fulvestrant
Kinase
Mutant
Pathology
Cancer research
Medicine
Cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations